Valuation
- Market cap
- 69,074,000
- Revenue TTM
- $0
- Net income TTM
- $-22,450,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 52,600
- Avg volume
- 124,118
- Day's range
- $4.70 – $4.90
- Shares out
- 14,542,000
- Stochastic %K
- 22%
- Beta
- -0.88
- Analysts
- Strong Sell
- Price target
- $21.20
Company profile
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210...
Show more
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 913 942 2300
- Website
- https://www.cingulate.com
- Address
- 1901 West 47th Place, Kansas City, United States
Latest news
No headlines yet.
